PCV53 COST-EFFECTIVENESS OF THE CNIC POLYPILL - FIXED DOSE COMBINATION OF ACETYLSALICYLIC ACID, RAMIPRIL AND ATORVASTATIN - FOR THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN GREECE
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.778
https://www.valueinhealthjournal.com/article/S1098-3015(19)33156-0/fulltext
Title :
PCV53 COST-EFFECTIVENESS OF THE CNIC POLYPILL - FIXED DOSE COMBINATION OF ACETYLSALICYLIC ACID, RAMIPRIL AND ATORVASTATIN - FOR THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN GREECE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)33156-0&doi=10.1016/j.jval.2019.09.778
First page :
Section Title :
Open access? :
No
Section Order :
10678